Ocuphire Pharma, Inc. Annual report pursuant to Section 13 and 15(d)

Apexian Sublicense Agreement (Details) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
	Nov. 05, 2020	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Sublicense Agreement [Abstract]
Common stock issued (in shares)	7,091,878
Program costs			$ 0	$ 1,769
Apexian Sublicense Agreement [Member]
Sublicense Agreement [Abstract]
Common stock issued (in shares)			843,751
Payment for license agreement				$ 2,100
Program costs			$ 400
Apexian Sublicense Agreement [Member] \| Development and Regulatory Milestones [Member] \| Maximum [Member]
Sublicense Agreement [Abstract]
Milestone payments			11,000
Apexian Sublicense Agreement [Member] \| Sales Milestones [Member] \| Maximum [Member]
Sublicense Agreement [Abstract]
Milestone payments			$ 20,000
Ref-1 Inhibitor Program [Member]
Sublicense Agreement [Abstract]
Program costs		$ 300